• Bertelsmann Investments acquires pharma tech company EXTEDO
  • Investment in the eight-digit range
  • Strategic step towards developing and expanding digital health expertise
  • € 90 million invested in the digital healthcare market since 2022

Gütersloh / Munich, February 15, 2024 – Bertelsmann Investments (BI) is acquiring the pharma tech company EXTEDO from European technology company IABG for an eight-digit sum. EXTEDO, based in the greater Munich area, was founded in 2003 within IABG Group to help companies in the pharmaceutical industry comply with regulatory requirements for the drug and medical device lifecycle. Today, EXTEDO is a leading provider of software solutions and services in the field of Regulatory Information Management, with a client list that includes both industrial customers and public authorities.


Carsten Coesfeld, CEO of Bertelsmann Investments, says: “EXTEDO’s development is an entrepreneurial success story in the digital healthcare market and I am very excited that the company is going to be part of our Bertelsmann Next portfolio. We will continue to strategically grow the topic of pharma tech in this unit. The potential and synergies we see in conjunction with our portfolio companies Docuvera and ROTE LISTE are extremely promising. We warmly welcome the EXTEDO team led by Martin Schmid to Bertelsmann Investments. My sincere thanks go to Prof. Dr. Schwarz, who has developed EXTEDO to this point within the IABG Group with his entrepreneurial flair."

Deniz Pielsticker, CFO of Bertelsmann Investments, says: "The acquisition of EXTEDO is another milestone in the expansion of our Pharma Tech unit, which we will continue to strengthen in the months and years ahead, through organic initiatives as well as targeted purchases."

Peter Koop, Senior Vice President Bertelsmann Investments, adds: “The European healthcare market offers enormous growth opportunities for pharma tech services. Bertelsmann Investments is now very well positioned to participate in this market. The acquisition of EXTEDO significantly expands our knowledge in the pharma tech sector.”

Prof. Dr.-Ing. Rudolf F. Schwarz, Managing Partner of IABG, says: “I am delighted that we have found a buyer, in Bertelsmann Investments, who will expand and further develop EXTEDO as an international player in the pharma tech market long-term. I am sure that synergy effects will quickly begin to materialize. At the same time, I would like to thank the EXTEDO management and all employees for more than two decades of excellent work as part of the IABG Group.”

Martin Schmid, CEO of EXTEDO, says: “We are proud to be driving digital healthcare forward and ultimately improving patient health and safety as a new part of Bertelsmann Investments. Enhancing synergies within the Bertelsmann Group will enable us to better meet the future needs of global life sciences organizations, regulators, and patients.”


About Bertelsmann Investments
Bertelsmann Investments (BI) comprises Bertelsmann’s global venture capital activities as well as the Bertelsmann Next growth unit. The venture capital arm includes the Bertelsmann Asia Investments (BAI), Bertelsmann India Investments (BII) and Bertelsmann Digital Media Investments (BDMI) funds, as well as selected fund and direct holdings in markets including Europe, the United States, Brazil, Southeast Asia and Africa. The Bertelsmann Next unit advances the entrepreneurial development of new growth sectors and business areas, including digital health, mobile gaming and HR Tech. To date, around €1.7 billion has been invested in more than 400 innovative companies and funds through Bertelsmann Investments. Bertelsmann Investments currently holds over 300 active investments worldwide through its network of start-ups and funds.

EXTEDO is a leading provider of software solutions and services for life sciences organizations in the field of Regulatory Information Management (RIM). EXTEDO's comprehensive solution platform, EXTEDOpulse, empowers industry and authorities to comply with regulations and efficiently manage information along the entire medicinal product lifecycle. EXTEDO's product portfolio combines innovation with compliance and quality with usability. EXTEDO optimizes all regulatory business processes end-to-end, from document management and registration management over submission management to safety management. With around 1000 customers in over 65 countries, including more than 35 regulatory authorities, EXTEDO has been playing a key role in the development of regulatory standards for over 25 years. For more information, please visit EXTEDO's website at www.extedo.com.

About IABG
Industrieanlagen-Betriebsgesellschaft mbH (IABG) is a leading European technology company with core competencies in analysis, simulation & testing and plant operation. The term “safety” forms the thematic umbrella of its solutions portfolio: functional safety of newly developed high-tech products and means of transportation, as well as the safety of the state, economy, and society. In this context, IABG provides technical and scientific services for private and public customers in its main business areas of automotive, information & communication / civil security, mobility, energy & environment, aviation, aerospace, and defense. IABG employs 1,100 highly qualified staff at its headquarters in Ottobrunn as well as in domestic and foreign branches that are close to its customers.

Please visit Bertelsmann Investments for the official announcement: Bertelsmann Investments Announces Another Major Investment in the Growing Pharma Tech Market





Latest Blog Posts


The Ukrainian eCTD in a Nutshell


EMA: New EU eCTD M1 Specification 3.1 and Validation Criteria 8.0


Interview: Meet EXTEDO’s eCTDtemplates!


Singapore's Transition to eCTD